Ventures

Rheumasense combines LC-MS biomarker testing with advanced machine learning to provide real-time, objective insights into rheumatoid arthritis (RA) disease activity. Our technology measures specific metabolites linked to RA progression, offering accurate, quantitative data for timely, personalized treatment adjustments. With a simple at-home blood collection kit and clinically validated testing at Mayo Clinic Laboratories, we deliver actionable results quickly and cost-effectively, improving patient outcomes and supporting proactive care.

DiaphOne TX is developing a first-in-class, orally available small-molecule therapy targeting the RAGE/DIAPH1 pathway, a central but underexploited disease axis in chronic metabolic and inflammatory conditions including type 2 diabetes, obesity and MASH. While existing treatments manage symptoms, they fail to address underlying disease progression. DiaphOne TX's approach targets the root of metabolic stress, inflammation and fibrosis, in a single platform with applicability across multiple high-value, multi-billion-euro markets.

MindAffect is redefining what’s possible in diagnostics. By harnessing Brain-Computer Interface technology and AI, we can “read” how the brain reacts to sound and visual stimuli—objectively, in real time, and without requiring a single response from the patient. At the core is our patented and clinically validated Rapid CAEP® technology, which captures the brain’s automatic reactions. This breakthrough allows clinicians to diagnose patients who would otherwise be difficult or impossible to test—such as infants, seniors, and individuals with disabilities. In a world where over two billion people are underserved by current diagnostic methods, this changes everything. Our first product, Sofi, is the world’s fastest objective hearing diagnostic system, delivering accurate hearing thresholds in minutes. Sofi has been validated in leading hospitals, championed by key opinion leaders across the audiology community, and recognized globally—winning the Innovation Award at the World Congress of Audiology

UltraTIL enables real-time tool-in-lesion confirmation during endobronchial lung cancer biopsies. This compact, side-viewing ultrasound probe is designed for the peripheral airways. UltraTil can be inserted through the working channel of a bronchoscope or robotic platform. By visualising lesions perpendicular to the airway and displaying the needle or biopsy instrument entering the target, UltraTIL improves the identification and sampling of small, eccentric and hard-to-reach lesions. The result: higher diagnostic accuracy, less reliance on additional positioning instruments, and shorter, more efficient procedures.

Sansepsis is a new treatment for sepsis, a serious condition causing many hospital deaths. Developed by Sanquin, a top blood bank in Europe, it uses a special filtering technology called apheresis to remove harmful pathogens from the blood. This innovative approach aims to improve patient outcomes and reduce the high costs associated with treating sepsis, offering hope for better management of this deadly condition.

Altach is tackling the challenge of treating damaged cartilage effectively without costly or complex procedures. Altach's solution is a simple, ready-to-use implant that makes microfracture treatment better. It's made from cartilage-like material and helps the body build new, healthy cartilage. This means fewer surgeries and better outcomes for patients.

Audaxis Medical revolutionizes the treatment of stress urinary incontinence with Plielle™, a next-generation polyurethane support system. While traditional polypropylene slings often lead to chronic inflammation and tissue complications, Plielle™ offers a safer alternative by replicating the native structure and viscoelastic properties of the pelvic floor. By providing a high-performance, biocompatible solution that integrates seamlessly with human tissue, Audaxis aims to improve clinical outcomes and restore patient confidence, filling a critical gap in women’s healthcare.

XtRNA Bio is developing a pioneering gene therapy to treat Charcot Marie Tooth (CMT) disease type 2D, leveraging tRNA supplementation therapies. Their patented treatment targets mutations in tRNA synthetases, offering a new therapeutic modality with vast potential for various diseases. They are raising €5M to develop a clinical candidate for CMT2D and expand their pipeline. CMT, a hereditary and heterogeneous disease, affects 1 in 2500 people worldwide, causing progressive muscle wasting, loss of sensation, and chronic pain, with no current cure.